(Z)-LFM-A13

SKU: orb1300970

Description

LFM-A13

Research Area

Cardiovascular Research, Cell Biology, Epigenetics & Chromatin, Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 244240-24-2
• MW: 360
• Purity: 99.88% (May vary between batches)
• Formula: C₁₁H₈Br₂N₂O₂
• SMILES: N(C(/C(=C(/C)\O)/C#N)=O)C1=C(Br)C=CC(Br)=C1
• Target: PLK,BTK,JAK
• Solubility: H2O:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+40% PEG300+5% Tween-80+45% Saline:2.5 mg/mL (6.94 mM);DMSO:67 mg/mL (186.11 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  BTK:2.5 μM
• In Vivo:
  In BALB/c mice bearing BCL-1 leukemia, combination of(Z)-LFM-A13 (50 mg/kg/day i.p.) and the standard triple-drug VPL prolongs the median survival time. In primary myeloma-bearing SCID-rab mice,(Z)-LFM-A13 inhibits osteoclast activity, prevents myeloma-induced bone resorption and suppresss myeloma growth.
• In Vitro:
  In BTK+ B-lineage leukemic cells, (Z)-LFM-A13 enhances their sensitivity to ceramide- or vincristine-induced apoptosis. In BCL-1 cells, NALM-6 cells, or normal BALB/c splenocytes, LFM-13 inhibits the enzymatic activity of BTK in BCL-1 cells without affecting the BTK protein expression levels In human neutrophils, (Z)-LFM-A13 decreases the tyrosine phosphorylation induced by fMet-Leu-Phe and inhibits the production of superoxide anions and the stimulation of adhesion, chemotaxis, and phospholipase D activity.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BTK, Btk, Bruton tyrosine kinase, PLK, JAK, Janus kinase, inhibit, Inhibitor, LFM A13, LFMA13, LFM-A13, LFM-A-13, Polo-like Kinase (PLK)

Compound Identifiers

PubChem CID

54676905